MangoRx aims to capitalize on growing demand for GLP-1 treatments to drive revenue growth and expand market share in the weight loss ...

With early phase 1 data now out in the wild, metabolic disease outfit Metsera is wasting no time locking down supplies of its ...

Kailera Therapeutics has launched into the increasingly crowded obesity space with a portfolio of assets acquired from China ...

Fueled by the rise of the blockbuster GLP-1 drugs, including Ozempic and Wegovy, thinness appears to be making a comeback in ...

CVS Health is exploring options that could include a breakup of the company to separate its retail and insurance units ...

Results of a recent study found that glucagon-like peptide-1 receptor agonists (GLP-1RAs) were associated with a lower risk ...

Securing a prescription for GLP-1s can be pricey — and not to mention, sometimes quite frustrating and invasive. But safety ...

If you’ve been trying to reach a healthier weight, you may be considering semaglutide medications like Ozempic and Wegovy.

A systematic review reveals that GLP-1 receptor agonists may help reduce certain substance use disorders, but findings are inconsistent due to study variability and patient differences. Review: ...

As the obesity epidemic continues rising, many physicians recognize the urgent need for specialized training beyond ...

Many people who take GLP-1 drugs find that their cravings disappear. I went to a Buddhist monastery to try to understand why ...

A series of state and federal lawsuits challenging coverage exclusions for obesity drugs and procedures are testing the ...